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Understanding how pathogenic mycobacteria subvert
the protective immune response is crucial to the devel-
opment of strategies aimed at controlling mycobacterial
infections. Prostaglandin E2 exerts an immunosuppres-
sive function in the context of mycobacterial infection.
Because cyclooxygenase-2 (COX-2) is a rate-limiting en-
zyme in prostaglandin biosynthesis, there is a need to
delineate the mechanisms through which pathogenic
mycobacteria regulate COX-2 expression in macro-
phages. Our studies demonstrate that the NF-B and
CRE elements of the COX-2 promoter are critical to My-
cobacterium avium-induced COX-2 gene expression.
M. avium-triggered signaling originates at the Toll-like
receptor 2 (TLR2). Ras associates with TLR2 and acti-
vates the mitogen-activated protein kinase (MAPK) ex-
tracellular signal-regulated kinase (ERK), whereas
tumor necrosis factor receptor-associated factor 6
(TRAF6)/transforming growth factor -activated kinase
1 (TAK1)-dependent signaling activates p38 MAPK. Both
ERK and p38 MAPK activation converge to regulate the
activation of mitogen- and stress-activated kinase 1
(MSK1). MSK1mediates the phosphorylation of the tran-
scription factor CREB accounting for its stimulatory
effect on CRE-dependent gene expression. M. avium-
triggered cytoplasmic NF-B activation following IB
phosphorylation is necessary but not sufficient for
COX-2 promoter-driven gene expression. MSK1 activa-
tion is also essential for M. avium-triggered NF-B-
dependent gene expression, presumably mediating
nucleosomal modifications. These studies demonstrate
that the nuclear kinase MSK1 is necessary in regulating
the pathogen-driven expression of a gene by controlling
two transcription factors. The attenuation of MSK1 may
therefore have potential benefit in restricting survival
of pathogenic mycobacteria in macrophages.
To design novel therapeutics and to rationalize vaccination
strategies against mycobacterial diseases, it is of foremost im-
portance to understand the mechanisms by which mycobacte-
ria subvert the protective immune response. The response of
macrophages to invasion by intracellular pathogens such as
mycobacteria depends on the signals triggered during the ini-
tial contact of the bacterium with the macrophages. Prosta-
glandin E2 (PGE2)
1 is believed to exert an immunosuppressive
function in the context of mycobacterial infections. PGE2 inter-
feres with T lymphocyte responses by inhibiting the production
of interleukin-2 (1). PGE2 also inhibits the secretion of inter-
feron-, which is important in activating T cells and macro-
phages (2). Cooper and colleagues (3) reported that the ability
of the virulentMycobacterium avium to attenuate macrophage
activation was dependent on its ability to trigger p38 mitogen-
activated protein kinase (MAPK)-dependent production of
PGE2. These observations were supported by a case report in
which monocytes from a child with disseminated M. avium
infection demonstrated a defect in bactericidal activity which
could be offset by treatment with indomethacin (4). The critical
role of PGE2 is also supported by a report that human immu-
nodeficiency virus envelope glycoprotein (gp120) can enhance
M. avium replication within macrophages by induction of
PGE2 (5).
Cyclooxygenase-2 (COX-2) is a key enzyme catalyzing the
rate-limiting step in the inducible production of prostaglan-
dins. COX-2 catalyzes the conversion of arachidonic acid to
PGH2, which is then metabolized by terminal synthases to a
variety of biologically active prostanoids (6). COX-2 gene ex-
pression is regulated at the level of transcription as well as
post-transcriptionally. The regulation of the COX-2 promoter
in macrophages is complex and involves different promoter
elements. The transcriptional activation of the COX-2 gene
depends on the stimulus-coupled binding of transcription fac-
tors (7), including NF-B, C/EBP, and AP-1 (8–12). The CRE-
element is the most generally required promoter element, be-
ing essential for both basal and induced COX-2 transcription in
a variety of cell types (13–17). The specific factors regulating
COX-2 induction depend on the cell type as well as on the
stimulus.
Considering that COX-2 is likely to play a critical role in
M. avium-triggered PGE2 release from macrophages, we set
out to explore the signaling cascades and the cis-regulatory
elements governing COX-2 induction from M. avium-chal-
lenged macrophages. Our results demonstrate that TLR2-
dependent ERK and p38 activation converge upon the activa-
tion of mitogen- and stress-activated kinase 1 (MSK1), which is
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instrumental in controlling both NF-B- and CRE-driven tran-
scription of the COX-2 gene. To the best of our knowledge, this
is the first demonstration of the role of MSK1 in controlling
pathogen-driven gene expression of COX-2, a molecule that
plays a central role in pathogenesis.
EXPERIMENTAL PROCEDURES
U0126, SB203580, H89, and manumycin A were purchased from
EMD Biosciences, San Diego, CA. Polymyxin B, CREBTIDE, anti-
CREB and anti-FLAG-agarose were products of Sigma. Protease inhib-
itors were from Roche Applied Science. Antibodies to MSK1, p65, and
p50 were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Antibodies specific for p38 MAPK, ERK, phospho-ERK, phospho-
p38, phospho-CREB, and anti-Ras were from Cell Signaling Technology
(Beverly, MA). Anti-TLR2 antibody was from Imgenex India (Bhu-
baneswar). [-32P]ATP was from Jonaki, BRIT (Hyderabad, India).
Growth of M. avium—M. avium (NCTC 8562) was obtained from the
All India Institute of Medical Sciences, New Delhi), grown in Middle-
brook 7H9 broth (Difco, Detroit, MI) supplemented with oleic acid-
albumin-dextrose supplement and 0.04% Tween 80 until mid-log phase,
harvested, washed, and resuspended in a small volume of phosphate-
buffered saline (PBS) containing 0.04% (v/v) Tween 80. The suspension
was briefly sonicated until no bacterial clumps were visualized by
microscopy. The preparation was diluted to a concentration of 2  108
colony-forming units/ml in 10% glycerol and stored in aliquots at
80 °C. Freshly thawed aliquots were used no more than once. Where
indicated, cells were incubated with polymyxin B (10 g/ml) for 30 min
prior to use.
Cell culture—The murine macrophage cell line RAW264.7 was ob-
tained from the National Centre for Cell Science, Pune, India, and
cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 2 mM glutamine, and antibiotics. Where indi-
cated, RAW264.7 cells were challenged withM. avium at a multiplicity
of infection (m.o.i.) of 2.
Plasmid constructs—Using genomic DNA from RAW264.7 cells as
template, the COX-2 promoter region (891 to 9) was amplified by
PCR using the primer pair 5-CGGGGTACCCAAACACTGTTTCT-
GAAT-3 (sense, primer a) and 5-ATAAAGCTTTTTGACAACTGGCT-
GCTA-3 (antisense, primer b). The resulting COX-2 promoter region
was cloned into the vector pGL2 Basic (Promega) harboring the pro-
moter-less luciferase gene, using asymmetric KpnI and Hind III sites
(underlined) to generate the plasmid pCOX301. NF-B(402/392),
C/EBP(135/130), AP-1(65/60), or CRE(60/56) binding sites
were mutated by deleting the underlined bases from the respective sites
as indicated: 5-GGGGATTCC-3 (for NF-B), 5-TCTTGCGCAA-3 (for
C/EBP), 5-ACAGAGTCAC-3 (for AP1) and 5-CACTACGTCA-3(for
CRE). Mutants were generated by overlap extension PCR. The primers
used are depicted in Table I. The initial rounds of PCR were carried out
using the primer pairs a and b for one reaction, c and d for the second
reaction, and pCOX301 as template. The products of each PCR were
purified and used as templates for the second round of PCR using the
primers a and d. The final products were cloned between the KpnI and
HindIII sites of pGL2 Basic. Vectors for wild type and dominant-nega-
tive Ras (Ras S17N); wild type and dominant-negative (S32A, S36A)
IB in pCMV were purchased from BD Biosciences. For generating
FLAG-tagged Ras expression vectors, the respective genes were excised
from the parent vectors described above using EcoRI and BamHI and
cloned between the EcoRI and BamHI sites in pFLAG-CMV6c. Wild
type and dominant-negative (amino acid residues 289–522) TRAF6 in
pRK-FLAG were gifts from Tularik Inc. Wild type and dominant-neg-
ative (K63W) HA-TAK1 were gifts from Dr. Kuni Matsumoto, Nagoya
University, Japan; wild type and dominant-negative (D195A) MSK1 in
pCMV-FLAG were gifts from Dr. Dario Alessi, University of Dundee,
UK. Wild type TLR4 (mTLR4) in pEF-Bos was a gift from Dr. Yoshinori
Nagai of the University of Tokyo, Japan. Dominant-negative mTLR4
(P712H) was generated by site-directed mutagenesis based on the prin-
ciple of overlap extension PCR. Using pEF-BOS-TLR4 as template, the
first round of PCR was performed with primer pairs a and b for one
reaction and primer pairs c and d for the second reaction. The second
round of PCR was performed using the products of the first round as
templates, and primers a and d. Primers a, b, c, and d were 5-ACAG-
AATTCTCAGCGTTCTTATCCCTT-3, 5-GACTTTATTCATGGTGTA-
GCC-3, 5-GGCTACACCATGAATAAAGTC-3, and 5-CGCGGATCC-
GGTCCAAGTTGCCGTTTC-3, respectively. The resulting 1.2-kb PCR
product was cloned in pUC19 between the EcoRI and BamHI sites,
sequenced on both strands, and an Xho-BamHI (468 bp) fragment
containing the mutated TLR4 gene encoding amino acid residues 679–
835 was then excised and used to replace the Xho-BamHI fragment of
wild type TLR4 in pEF-BOS. p4NF-B-luc containing four NF-B sites
in tandem fused to the luciferase reporter gene, was a gift from Dr. A.
Brent Carter of the University of Iowa. The p6CRE-luc construct con-
taining 6 CRE sites in tandem fused to the luciferase reporter gene was
a gift from Dr. Steve Rees of GlaxoSmithKline. pGEX/Raf-RBD was a
gift from Dr. Robert J. Sheaff of the University of Minnesota. cDNA
products for murine TLR2 and CREB were obtained by reverse tran-
scription-PCR from a total RNA preparation from RAW264.7 cells using
the primer pairs: 5-CTAGCTAGCTAGATGCTACGAGCTCTT-3
(sense) and 5-CCGCTCGAGCGGCTAGGCCTTTATTGC-3 (antisense)
for TLR2; and 5-ATAAAGCTTATGGAATCTGGA-3 (sense) and 5-A-
TGGATCCATCTGATTTGTGGCAGTA-3 (antisense) for CREB. The
resulting PCR products were cloned in pcDNA3.1 (between NheI and
XhoI sites) for TLR2 and pFLAG-CMV-6a (between HindIII and BamHI
sites) for CREB. For generating dominant-negative dominant TLR2
(carrying a 13-amino acid deletion from the C terminus), a 2313-bp
fragment was amplified by PCR using the sense primer mentioned
above and the antisense primer: 5-CCGCTCGAGCGGCTGGCCT-
TCATC-3. The resulting PCR product was cloned in pcDNA 3.1 be-
tween NheI and XhoI sites. Site-directed mutagenesis was performed to
generate dominant-negative CREB (S133A). Primers b and c were
5-AGGAGGCCTGCCTACAGGAAA-3 and 5-TTTCCTGTAGGCAG-
GCCTCCT-3, respectively. All constructs were checked by sequencing
on both strands.
Enzyme Immunoassay for PGE2—Supernatants from mock-treated
and M. avium-treated macrophages were harvested at the indicated
times and tested for the presence of PGE2 using the BIOTRAK PGE2
assay kit from Amersham Biosciences.
Western Blotting—Proteins were separated by SDS-PAGE and then
transferred electrophoretically to polyvinylidene difluoride membranes.
The blots were blocked with 5% nonfat dry milk in Tris-buffered saline
(TBS) for 1 h at room temperature and subsequently incubated over-
night at 4 °C with primary antibodies in TBS-Tween 20 (1%, v/v)
(TBST) with 5% (w/v) bovine serum albumin. Following three washes of
5 min each with TBST, the blots were incubated with horse radish
peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology,
Inc.) (or appropriate secondary antibodies) in blocking buffer for 1 h at
room temperature. After three washes with TBST, the blots were de-
veloped by chemiluminescence using the Phototope-HRP Western blot
detection kit (Cell Signaling Technology) and exposed to x-ray film
(Kodak XAR5).
RNA Isolation and Reverse Transcription-PCR—Total RNA was pre-
pared from cells using the RNeasy Mini kit (Qiagen) according to the
manufacturer’s protocol. 100 ng of RNA was reverse-transcribed using
the Titan 1-tube reverse transcription-PCR Kit (Roche Applied Sci-
ences). The sense primer 5-GGGTTGCTGGGGGAAATGTG-3, and the
antisense primer 5-GGTGGCTGTTTTGGTAGGTG-3, were used to
amplify 479 bp of COX-2 mRNA. Glyceraldehyde-3-phosphate dehydro-
genase was amplified using the primers: 5-CCA TCA ATG ACC CCT
TCA TTG ACC-3 (sense), and 5-GAA GGC CAT GCC AGT GAG CTT
CC-3 (antisense) to generate a 604-bp product. The PCR conditions for
COX-2 mRNA were denaturation at 94 °C for 30 s, annealing at 50 °C
for 1 min, and extension at 68 °C or 1 min for 35 cycles.
TABLE I
Primers used for mutation of transcription factor binding sites in the murine COX-2 promoter
Primers “b” and “c” are defined under “Experimental Procedures.”
Mutation at the
binding site for Primer b Primer c
NFB 5-GGGGAGAGGTGAGGGTTCCCTTAGTTAGGA -3 5- TCCTAACTAAGGGAACCCTCACCTCTCCCC-3
C/EBP 5- TGCCGCTGCGGTTCTGCCACTCACTGAAGCAGA-3 5-TCTGCTTCAGTGAGTGGCAGAACCGCAGCGGCA-3
AP1 5-AGCGGAAAGACAGAGCCACTACGTCACGTG -3 5- CACGTGACGTAGTGGCTCTGTCTTTCCGCT-3
CREB 5-AGACAGAGTCACCACTTCACGTGGAGTCCGCTT-3 5-AAGCGGACTCCACGTGAAGTGGTGACTCTGTCT-3
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Electrophoretic Mobility Shift Assay—To prepare nuclear extracts,
plates with adhered cells were washed twice with ice-cold PBS and
scraped in ice-cold TNE buffer (40 mM Tris HCl, pH 7.5, 0.1 M NaCl, 1
mM EDTA). Cells were pelleted at 600  g for 1 min, and pellets were
resuspended in 400 l of lysis buffer (10 mM HEPES, pH 7.9, 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM Pefabloc,
2 g/ml leupeptin, 2 g/ml aprotinin, 0.5 mg/ml benzamidine). Cells
were lysed by the addition of 23 l of 10% (v/v) Nonidet P-40 (Nonidet
P-40) and the nuclear pellet was suspended in 25 l of ice-cold extrac-
tion buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiothreitol, 0.5 mM Pefabloc, 2 g/ml leupeptin, 2 g/ml
aprotinin, 0.5 mg/ml benzamidine), kept on ice for 30 min with occa-
sional mixing, and centrifuged at 10, 000  g for 5 min at 4 °C. The
supernatant (nuclear extract) was immediately frozen and stored at
70 °C. Typically, 15 g of nuclear extract was incubated on ice for 5
min in the absence or presence of competitor DNA in a volume of 20 l
containing 4 l of 5 binding buffer (125 mM HEPES, pH 8, 2.5 mM
EDTA, 2.5 mM dithiothreitol, 5% Nonidet P-40, 250 mM NaCl, 20% (v/v)
glycerol), and 0.75 g of poly(dI-dC) as nonspecific competitor DNA. The
32P-end-labeled double-stranded oligonucleotides (60,000 cpm per reac-
tion) containing the COX-2 gene-specific NF-B binding site (5-GGT-
GAGGGGGATTCCCTTAGTTA-3) (or the mutated oligonucleotide
with the sites of mutation (GA3 CC) in boldface) or the COX-2-specific
CRE site (5-GTCACCACTACGTCACGTGGAG-3) (or the mutated oli-
gonucleotide with the sites of mutation (ACG 3 GAT) in boldface) was
added, and the mixture was incubated for 30 min at 25 °C. The DNA-
protein complex formed was separated from the oligonucleotide on a 4%
native polyacrylamide gel. The gel was dried and analyzed by autora-
diography. For supershift assays, nuclear extracts were incubated for
30 min at 25 °C with rabbit polyclonal antibodies against p50, p65 (for
NF-B), or CREB (for CRE) or no antibody before incubation with the
radiolabeled probe.
Luciferase reporter assays—Cells were transfected with luciferase
reporter plasmid. Transfected cells were challenged with M. avium,
washed once with PBS, and scraped into luciferase lysis buffer (50 mM
Tris, pH 8, 70 mM K2HPO4, 0.1% Nonidet P-40, 2 mM MgCl2, 1 mM
dithiothreitol, 20 g/ml aprotinin, 10 g/ml pepstatin, 10 g/ml leupep-
tin). The lysates were rapidly mixed, and insoluble material was pel-
leted by centrifugation at 4 °C. The supernatant was removed and
stored at 80 °C. For promoter activation analysis, luciferase activity
FIG. 1. M. avium stimulates PGE2
release and COX-2 expression in
RAW264. 7 cells. A, 2  105 cells were
treated with M. avium for 8 h, and the
culture medium was collected and as-
sayed for the release of PGE2 using the
BIOTRAK PGE2 ELISA kit according to
the manufacturer’s protocol. Where indi-
cated, cells were left untreated or treated
with U0126 (15 M) or SB203580 (5 M) or
wortmannin (200 nM), or a combination of
U0126 and SB203580 at the same concen-
trations, or H89 (10 M), for 30 min fol-
lowed by the treatment with M. avium at
an m.o.i. of 2 for 8 h. The released PGE2
was measured as described. B, RAW264.7
cells were transfected with empty vector
(pcDNA3.1 or pEF-BOS) or with domi-
nant-negative(dn)-TLR4 [TLR4(P712H)]
or -TLR2, followed by treatment with M.
avium at an m.o.i. of 2 for 8 h. PGE2
release was subsequently assayed. Re-
sults shown represent the means  S.D.
of three independent experiments. C, 5 
105 cells were seeded in a 24-well plate,
treated withM. avium at an m.o.i. of 2 for
different periods of time periods as indi-
cated, washed, and lysed. The expression
of COX-2 in the lysates was analyzed by
Western blotting using anti-COX-2 anti-
body. The blot is representative of the
results obtained in three independent ex-
periments. D, cells were left untreated or
treated with U0126 (15 M) or SB203580
(5 M) or manumycin A (10 M) or a com-
bination of U0126 and SB203580 at the
same concentrations, or H89 (10 M) for
30 min followed by the treatment with
M. avium at an m.o.i. of 2 for 8 h. Expres-
sion of COX-2 was analyzed as described
in panel C. The blot is representative of
results obtained in three independent ex-
periments; panel F represents the results
obtained from densitometric scanning of
these gels (means  S.D.). E, cells were
left untreated or pretreated with the in-
hibitors SB203580 (5 M) or U0126 (15
M) or a combination of U0126 and
SB203580 at the same concentrations, or
H89 (10 M) for 30 min followed by the
treatment with M. avium at an m.o.i. of 2
for 6 h. Total RNA was isolated and re-
verse transcription-PCR was performed
using primers specific for the COX-2 or
the glyceraldehyde-3-phosphate dehydro-
genase (gapdh) genes. The products were
visualized on agarose gels by ethidium
bromide staining. The data shown are
representative of results obtained from
three independent experiments.
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assays were performed in a luminometer, and the results were normal-
ized for transfection efficiencies by assay of -galactosidase activity.
Ras Activity Assay—Ras activity was measured by assaying for Ras
proteins bound to the Ras-binding domain of Raf-1 expressed as a GST
fusion protein (18). Briefly, cells (2  106) after treatment were washed
with ice-cold PBS, lysed in lysis buffer (25 mM HEPES, pH 7.5, 150 mM
NaCl, 10 mM MgCl2, 5 mM EDTA, 25 mM NaF, 1 mM sodium orthovana-
date, 10% glycerol, 10 g/ml aprotinin, and 10 g/ml leupeptin) and
centrifuged. Lysate was incubated with 5 g of Ras-binding domain of
Raf-1 (Raf-1 RBD) at 4 °C for 3 h with gentle agitation, and the beads
were washed thrice in lysis buffer. Bound Ras proteins were solubilized
in Laemmli buffer and detected by SDS-PAGE followed by Western
blotting using anti-Ras antibody.
Co-immunoprecipitation of Ras with TLR2—RAW 264.7 cells were
transfected with FLAG-Ras expressing vector and challenged with
M. avium for the indicated time periods. The cells were harvested,
lysed in lysis buffer (40 mM Tris-HCl (pH 8.0), 500 mM NaCl, 0.1%
Nonidet P-40, 6 mM EGTA, 10 mM sodium -glycerophosphate, 10 mM
NaF, 300 M sodium orthovanadate, 2 mM phenylmethylsulfonyl
fluoride, 10 g/ml aprotinin, 1 g/ml leupeptin, and 1 mM dithiothre-
itol), and centrifuged. The supernatant was then immunoprecipitated
with anti-FLAG-agarose. The immunoprecipitated beads were
washed three times with lysis buffer. The samples were fractionated
on 15% SDS-polyacrylamide gels, transferred to a polyvinylidene
difluoride membrane, and subjected to immunoblot analysis with
antibodies specific for TLR2.
MSK1 Assay—Cells were washed with ice-cold PBS and lysed in lysis
buffer containing 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1
mM sodium orthovanadate, 1% (v/v) Triton X-100, 50 mM NaF, 5 mM
sodium pyrophosphate, 0.27 M sucrose, 0.1%(v/v) -mercaptoethanol, 1
mM benzamidine, 2 g/ml leupeptin, and 0.2 mM Pefabloc. Lysates were
clarified by centrifugation (5 min, 10,000  g, 4 °C). MSK1 was immu-
noprecipitated by incubation with anti-MSK1 antibody. The immuno-
precipitates were washed three times with lysis buffer and twice with
kinase buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 0.1 mM EGTA, 10
mM NaF, and 0.1% (v/v) -mercaptoethanol). Beads were resuspended
in 50 l of kinase buffer containing 30 M substrate peptide: EILSR-
RPSYRK (CREBTIDE) and 0.1 mM [-32P]ATP (20,0000 cpm/pmol).
After incubation at 30 °C for 30 min, the incorporation of phosphates in
CREBTIDE was determined using p81 phosphocellulose paper (19).
RESULTS
M. avium Stimulates PGE2 Release from RAW264.7 Macro-
phages—Considering that PGE2 release is one of the mecha-
nisms used by virulent M. avium to down-regulate macrophage
activation (3), we sought to investigate the mechanisms of
M. avium-stimulated PGE2 release from RAW264.7 macro-
phages. The levels of PGE2 released from RAW264.7 cells were
measured using an enzyme-linked immunosorbent assay. Chal-
lenge of macrophages with M. avium for 8 h induced a rise in
PGE2 levels (Fig. 1A). Members of the TLR protein family are key
regulators of innate immune activation induced by pathogenic
mycobacteria (20). M. avium signals in macrophages through
TLR2 (21). Consistent with a role of TLR2-dependent signaling in
M. avium-stimulated PGE2 release, transfection of RAW264.7
cells with dominant-negative TLR2, led to abrogation of PGE2
release following M. avium challenge (Fig. 1B). On the other
hand, cells transfected with dominant-negative TLR4 (TLR4 har-
boring the mutation P712H) still showed release of PGE2 when
challenged withM. avium. In results described in Fig. 5, we have
validated that TLR4(P712H) does function as a dominant-
negative in the present context. TLR4 therefore did not appear to
play any role in M. avium-mediated PGE2 release.
M. avium-stimulated PGE2 Release Depends on the ERK and
p38 MAPKs—PGE2 release from M. avium-challenged cells
was inhibited when cells were pretreated with pharmacological
inhibitors of ERK and p38 MAPKs, U0126 and SB203580,
respectively (Fig. 1A). Although other effectors such as bacte-
rial peptidoglycan have been reported to modulate PGE2 re-
lease by activating COX-2 expression in a phosphatidylinositol
3-kinase-dependent manner, the phosphatidylinositol 3-kinase
inhibitor wortmannin had no effect on PGE2 release in the
present instance. The ERK and p38 MAPKs appeared to regu-
FIG. 2.M. avium activates Ras in RAW264.7 cells in a TLR2-de-
pendent manner. RAW264.7 cells were challenged with M. avium for
different periods of time as indicated and lysed, and lysates were
incubated with 5 g of GST-Raf-1 RBD immobilized on glutathione-
Sepharose at 4 °C for 3 h. Bound Ras proteins were solubilized in
Laemmli buffer and detected by SDS-PAGE and Western blotting using
anti-Ras antibody.Panel A is a representative blot.Panel B represents the
results from densitometric scans of the blots from three independent
experiments (means  S.D.). C, cells were transfected with either empty
vector (pcDNA3.1) or dominant-negative TLR2 (TLR2 (dn)), then left
untreated or treated withM. avium at an m.o.i. of 2 for 4 min. Cell lysates
were prepared, and Ras activity was measured as described. The blot
shown is representative of results obtained in three independent experi-
ments. D, the densitometric scan of three independent experiments
(means  S.D.). For panels A and C, actin immunoblots indicate equal
loading in all lanes. E, RAW264.7 cells were transfected with FLAG-
tagged Ras (Flag-Ras) or an irrelevant FLAG-tagged construct (Flag-irr)
and treated with M. avium for the indicated time periods. Cell extracts
were immunoprecipitated with anti-FLAG agarose and then immuno-
blotted with anti-TLR2 antibody or irrelevant antibody (anti-irr). The
bottom panel was obtained by immunoblotting with anti-FLAG. The blots
are representative of results obtained in three independent experiments.
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late PGE2 release in a synergistic manner, because a combina-
tion of the inhibitors U0126 and SB203580 led to a complete
inhibition of PGE2 release (Fig. 1A). Besides their ability to
phosphorylate and activate transcription factors, both ERK
and p38 MAPK also transduce signals by activating down-
stream kinases such as mitogen- and stress-activated protein
kinase 1 (MSK1), which in turn phosphorylates transcription
factors. Cells pretreated with H89, a pharmacological inhibitor
of MSK1, at the dose used led to a complete inhibition of PGE2
release (Fig. 1A), suggesting a role of MSK1 in PGE2 release.
M. avium Stimulates COX-2 Expression—COX-2 converts
arachidonic acid released from the cell lipids by the action of
phospholipase A2 to prostaglandin H2, the common precursor
of all prostaglandins. To examine whether elevated PGE2 syn-
thesis is associated with increased COX-2 expression we
studied the M. avium-induced expression of COX-2. Western
analysis showed that M. avium challenge resulted in a time-
dependent increase in the expression of COX-2 in RAW264.7
(Fig. 1C)
COX-2 expression is regulated by, among others, transcrip-
tional mechanisms (7–12). We therefore analyzed the expres-
sion of the COX-2 gene in M. avium-challenged macrophages
by reverse transcription-PCR. Compared with untreated cells,
the steady-state COX-2 mRNA levels increased in cells treated
with M. avium (Fig. 1E). Taken together, our results on acti-
vation of COX-2 at the level of the gene and the protein in cells
challenged with M. avium suggested that this regulation is
likely to be critical in controlling PGE2 release from these cells.
M. avium-induced COX-2 Expression Is Dependent on the
MAPKs—Considering the role of MAPK inhibitors in inhibiting
PGE2 release, we tested the role of MAPKs in M. avium-
induced COX-2 expression. As shown in Fig. 1 (D and F),
M. avium-induced COX-2 expression could be attenuated par-
tially either by U0126 or by SB203580 alone, suggesting a role
of ERK as well as p38 MAPKs in M. avium-triggered COX-2
expression. As in the case of PGE2 release, COX-2 expression
was completely inhibited either by a combination of U0126 and
SB203580, or by H89. The levels of COX-2 mRNA were also
similarly regulated (Fig. 1E). These results suggested the pos-
sibility that COX-2 gene expression is coordinately regulated
by ERK and p38 MAPKs regulating MSK1. This possibility has
been tested in the following sections.
Ras Is Involved in M. avium-induced COX-2 Expression—
The small GTP-binding protein Ras is an important signal
mediator in response to stimuli such as growth factors, cyto-
kines, and hormones (22). In resting cells, Ras is maintained in
FIG. 3. M. avium-dependent activation of ERK and p38 MAPKs. A, RAW264.7 cells were left untreated or incubated with different
concentrations of manumycin A for 30 min, followed by treatment with M. avium for 20 min. Cells were washed, lysed, and immunoblotted with
phospho-ERK. All blots were reprobed with appropriate non-phospho antibodies to confirm equal loading. Blots shown are representative of results
obtained in three independent experiments. The bars in panel B represent the results obtained by densitometric scans of three different blots
corresponding to panel B (means  S.D.). For panels C and D, RAW264.7 macrophages were transfected with empty vector (pcDNA3.1, pRK5, and
pCMV for TLR2, TRAF6, and TAK1 constructs, respectively) or dominant-negative constructs followed by treatment with M. avium for 20 min.
Cells were washed, lysed, and immunoblotted with phospho-ERK (C) or with phospho p38 (D) as described above.
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an inactivated Ras-GDP form. After activation, Ras is con-
verted into active Ras-GTP. Ras exerts its function through
activating downstream effectors, among which the best studied
is the MAPK cascade (23). Considering the role of ERK and p38
MAPKs in regulating PGE2 release as well as COX-2 expres-
sion in response to M. avium challenge, we tested the effect of
the Ras inhibitor manumycin A (24) on M. avium-induced
COX-2 expression. Cells were pretreated with manumycin A
prior to challenge with M. avium. Manumycin A partially in-
hibited M. avium-induced COX-2 expression (Fig. 1, D and F).
To further confirm the role of Ras in M. avium-induced signal-
ing in RAW264.7 cells, the activation of Ras was assessed by an
activation assay relying on the interaction of activated Ras
with Raf-1-RBD (18). Upon M. avium challenge, Ras activity
increased in a time-dependent manner (Fig. 2, A and B). Taken
together, these results suggested that M. avium-induced
COX-2 expression depends on Ras activation.
TLR2 Associates with Ras in M. avium-stimulated Macro-
phages—BecauseM. avium-mediated PGE2 release is inhibited
by dominant-negative TLR2, we tested the hypothesis that
rapid Ras activation could be linked to TLR2 signaling. It was
observed that M. avium-induced Ras activation was blocked in
cells transfected with dominant-negative TLR2 (Fig. 2, C and
D). To test whether rapid Ras activation is concurrent with
Ras-TLR2 interaction, RAW264.7 cells were transfected with
FLAG-tagged Ras and challenged with M. avium, and lysates
were prepared and immunoprecipitated with anti-FLAG anti-
body and immunoblotted for the presence of TLR2 in the im-
munoprecipitated complex. The association of Ras and TLR2
occurred in a time-dependent manner (Fig. 2E). The immuno-
precipitate showed no band corresponding to TLR2 when it was
blotted with an irrelevant antibody. Control experiments were
performed in which an irrelevant FLAG-tagged protein was
transfected prior to challenge with M. avium. Co-immunopre-
cipitation of TLR2 with anti-FLAG antibody was not visible in
this case. Taken together, all these results suggested that
M. avium-induced Ras activation occurs through interaction of
Ras with TLR2.
M. avium-induced ERK Activation Depends on TLR2/Ras
Signaling—Our previous studies have already demonstrated
thatM. avium activates ERK and p38 MAPKs in macrophages
(25). In the present study we observed that pretreatment with
manumycin A (Fig. 3, A and B) inhibited the phosphorylation of
ERK in a dose-dependent manner. This suggested that ERK
was downstream of Ras signaling. Further, transfection of cells
with dominant-negative TLR2 or dominant-negative Ras led to
an inhibition of M. avium-induced ERK phosphorylation (Fig.
3C), supporting the view that M. avium activates ERK in a
TLR2/Ras-dependent signaling pathway.
M. avium-induced p38 MAPK Activation Depends on TLR2/
TRAF6 Signaling—M. avium-induced p38 MAPK activation
was inhibited by transfecting cells with dominant-negative con-
structs of TLR2, TRAF6, or TAK1 (Fig. 3D). TAK1 is known to
signal downstream of the TLRs to activate p38 MAPK in re-
sponse to a variety of stimuli (26, 27). Because TLR2/TRAF6/
TAK1 signaling is a well established pathway of MAPK acti-
vation, we felt it safe to predict that this pathway controls the
activation of p38 MAPK in the present instance also.
M. avium Stimulates COX-2 Promoter Activity—COX-2 ex-
pression is controlled by both transcriptional and post-tran-
scriptional mechanisms. To determine whether M. avium reg-
ulates COX-2 promoter activity, RAW 264.7 cells were
transfected with different constructs of the mouse COX-2 pro-
moter coupled with the luciferase reporter gene. M. avium
evoked at least a 10-fold increase in luciferase activity in cells
transiently expressing COX-2 promoter (891 to  9)-luc com-
FIG. 4. M. avium-stimulated COX-2 gene expression in
RAW264.7 depends on the NF-B and CRE elements of the COX-2
promoter. A, cells were transfected with a COX-2 promoter-luciferase
reporter construct or mutant constructs along with -galactosidase
expression vector. Transfected cells were either left untreated or
treated with M. avium at an m.o.i. of 2 for 6 h. Luciferase reporter
activities were measured in cell extracts using luciferin as a substrate.
The level of induction of luciferase activity was compared with that of
untreated cells. Data were normalized with respect to -galactosidase
activity. Results represent means  S.D. of three independent experi-
ments. B and C, electrophoretic mobility shift assays. RAW264.7 cells
were left untreated or challenged with M. avium for 3.5 h. The nuclear
extracts were subjected to EMSA using labeled COX-2-specific NF-B
(B) or CRE (C) DNA probes. Where required, the binding reaction was
performed in the presence of competitor (unlabeled) oligonucleotides or
supershift antibodies as indicated. The arrowheads indicate the posi-
tion of bands. Gels are representative of results obtained from three
independent experiments.
Mycobacteria-induced COX-2 Expression in Macrophages55132
 by guest, on August 30, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
pared with untreated cultures (Fig. 4A). To rule out the effect
of contaminating lipopolysaccharide (LPS) on COX-2 promoter-
activated gene expression, M. avium cells were first incubated
with polymyxin B before challenge of macrophages. The expres-
sion of luciferase was unchanged using polymyxin B-treated as
compared with untreated M. avium (Fig. 5A).
The NF-B and CRE Sites Are Essential for Optimal COX-2
Promoter-induced Reporter Induction in M. avium-stimulated
Macrophages—In macrophages, several cis-acting elements
have been found to play a role in COX-2 gene transcription
(7–12). To assess the role of the potential cis-acting elements in
M. avium-induced COX-2 gene transcription, the NF-B, CRE,
C/EBP, and AP-1 elements were individually mutated (as
depicted in Fig. 4A) to evaluate the effects of such mutations on
M. avium-stimulated COX-2 promoter activity. The COX-2 re-
porter constructs were transiently transfected into RAW264.7
macrophages. Cells were subsequently challenged with
M. avium for 6 h, harvested, and lysed for luciferase activity
reporter activity induced by M. avium. Our results demon-
strate that the constructs mutated at the AP-1 and C/EBP
sites were as effective in stimulating luciferase gene expression
as the wild-type COX-2 promoter (Fig. 4A). However, there was
partial inhibition of luciferase gene expression when either the
NF-B or the CRE site was mutated, suggesting thatM. avium-
induced COX-2 promoter activation depends on the NF-B as
well as the CRE elements. Luciferase expression was com-
pletely inhibited when both the NF-B and the CRE sites were
mutated (Fig. 4A).
IB- Phosphorylation Is Necessary for M. avium-driven
COX-2 Promoter Activation—In most cell types, NF-B is main-
tained in an inactive form in the cytoplasm by association with
IBs. In the better known mechanisms of NF-B activation, TLR
signaling leads to the IB kinase-dependent phosphorylation of
IB-, its ubiquitination and degradation by the proteasome,
accompanied by the release and subsequent translocation of
NF-B into the nucleus (28). The likely involvement of this clas-
sic pathway inM. avium-induced COX-2 promoter activation was
tested. Transfection with dominant-negative TLR2 led to an in-
hibition of M. avium-stimulated luciferase activity (Fig. 5B).
However, transfection with dominant-negative TLR4 (P712H)
had no effect on M. avium-stimulated luciferase activity (Fig.
5B). The behavior of TLR4 (P712H) as dominant-negative was
validated by the observation that this mutant could inhibit LPS-
driven luciferase activation (Fig. 5E), corroborating the observa-
FIG. 5. M. avium stimulates COX-2 promoter-driven luciferase reporter expression in RAW264.7. RAW264.7 cells were transfected
with the COX-2 promoter (891 to 9)-luciferase reporter and -galactosidase constructs. A, transfected cells were left untreated or treated with
U0126 (15 M), or SB203580 (5 M), or H89 (10 M), or a combination of U0126 and SB203580. Cells were then challenged for 6 h with M. avium
or with M. avium preincubated with polymyxin B (10 g/ml). In addition to the constructs mentioned above, cells were co-transfected (B and E)
with empty vectors or constructs as indicated; followed by challenge with M. avium (B) or with E. coli LPS (E) for 6 h. C and D, cells were
transfected with the 4 B-luciferase construct (C) or the 6 CRE-luciferase construct (D) instead of the COX-2 promoter-luciferase construct.
Transfected cells were treated with inhibitors (C and D) as described above. Cells were then left untreated or incubated with E. coli LPS or with
M. avium (as indicated in the panels) for 6 h. Following incubations, luciferase reporter activities in the cell extracts were measured using luciferin
as substrate. In each case, the level of induction of luciferase activity was compared with that of untreated cells. The activities shown represent
data that have been normalized with -galactosidase activity. Results represent the means  S.D. of three independent experiments.
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tions of Rhee and Hwang (29). Taken together, these results
suggested that M. avium-mediated COX-2 gene expression is
dependent on TLR2 but not on TLR4. The role of IB- phospho-
rylation was tested by transfecting cells with a mutated IB-
(S32A/S36A) construct in which the two critical serine residues,
which are phosphorylated by the IB kinases, have been mu-
tated; along with the COX-2 promoter-luciferase construct. Ex-
pression of the mutant IB protein partially blockedM. avium-
dependent activation of the COX-2 luc reporter (Fig. 5B),
indicating that the mutant IB protein was an effective repres-
sor of COX-2 promoter-driven reporter expression. Considering
that the phosphorylation and proteasome-mediated degradation
of IB is the classic pathway of cytoplasmic NF-B activation,
the partial inhibition by pCMV-IB-(S32A/S36A) was expected
and supported by our observations that transfection with the
mutant IB-(S32A/S36A) construct inhibitedM. avium-induced
4x B-driven luciferase expression (Fig. 5E). Canonical NF-B
activation was therefore required for M. avium-induced COX-2
reporter activity.
There are results both in favor and against a role of NF-B in
the stimulation of COX-2 gene expression. Whereas, NF-B ac-
tivates a COX-2 promoter construct in IL-1-stimulated pulmo-
nary type II A549 cells (30), it plays no role in COX-2 induction in
tumor necrosis factor--stimulated rat vascular smooth muscle
cells (31). Our present studies definitively show that M. avium-
stimulated gene expression driven by the COX-2 promoter de-
pends on the NF-B element on the COX-2 promoter.
We also examined whether the NF-B activation correlates
with differences in NF-B-specific DNA binding. Nuclear ex-
tracts were prepared from untreated cells as well as cells
treated for 3.5 h with M. avium. Extracts from M. avium-
treated cells showed binding to an oligonucleotide sequence
corresponding to the NF-B-binding site of the COX-2 promoter
(Fig. 4B), and DNA binding was inhibited by excess unlabeled
oligonucleotide. No binding was observed when a mutant NF-
B-binding oligonucleotide sequence was used (data not
shown). Supershift of the band obtained with the NF-B-spe-
cific oligonucleotide with anti-p65 or anti-p50 (Fig. 4B) sug-
gested that p65 and p50 are the components of the protein
complex that binds to the NF-B element of the COX-2
promoter.
The MAPKs ERK and p38 Regulate M. avium-induced
COX-2 Promoter Activation—To analyze the effect of ERK
and p38 MAPK activation on COX-2 promoter-driven lucifer-
ase expression in M. avium-challenged RAW264.7, cells were
pretreated with ERK and p38 MAPK-specific inhibitors
U0126 and SB203580, respectively. Both these inhibitors
caused a partial inhibition of luciferase expression (Fig. 5A).
However, a combination of both inhibitors completely inhib-
ited luciferase expression, suggesting that ERK and p38
MAPK activation are critical in sustaining M. avium-driven
COX-2 promoter activation.
MSK1 Is Activated in M. avium-stimulated Macrophages—
The MAPKs phosphorylate several downstream kinases, one of
which is MSK1, which is constitutively localized in the nucleus
where it regulates transcription by phosphorylating histone
H3, p65/RelA, and CBP/p300 (32, 33) leading to modification of
nucleosome conformation and increased accessibility of the
transcription machinery to promoters. ERK and p38 are both
known to activate MSK1 (34). To determine whether the effects
of ERK and p38 MAPKs are transmitted through the activation
of MSK1, we first investigated the ability ofM. avium to trigger
the activation of MSK1. MSK1 kinase activity was determined
in M. avium-treated macrophages by immunoprecipitating
MSK1 from cell lysates and assaying the ability of the immu-
noprecipitates to phosphorylate the peptide: EILSRRPSYRK
(CREBTIDE) (34).M avium activated MSK1 in a time-depend-
ent manner (Fig. 6A). MSK1 activity could be partially inhib-
ited by pretreatment with either U0126 or SB203580 (Fig. 6B),
suggesting a role of both ERK and p38 MAPK signaling in
MSK1 activation. A combination of U0126 and SB203580 com-
pletely blocked MSK1 activation (Fig. 6B), suggesting that
ERK and p38 MAPK act synergistically to activate MSK1. The
finding that both kinases are required for MSK1 activity raises
the possibility that they may phosphorylate non-overlapping
sites that affect the kinase activity of MSK1, or that the two
kinases regulate each other, or that the activity of neither of
the two kinases is sufficient to fully phosphorylate MSK1.
Whatever the mechanism, our findings suggest that MSK1
plays an essential role functioning as a downstream effector of
M. avium signaling controlling both NF-B- and CRE-driven
COX-2 promoter activation. The following sections detail our
attempts to address this question.
CREB Plays a Role in M. avium-induced COX-2 Promoter
Activation—CREB, a member of the ATF family of transcrip-
tion factors, binds to the CRE element. Because mutation of the
COX-2 CRE site inhibits COX-2 reporter activity, we explored
FIG. 6. M. avium-stimulated MSK1 regulates CREB phospho-
rylation in RAW264.7 macrophages. A, cells were left untreated or
treated with M. avium for different periods of time. Cell lysates were
immunoprecipitated with MSK1 antibody, and the immunoprecipitate
was used to measure the phosphorylation of the substrate CREB-tide as
described under “Experimental Procedures.” B, cells were incubated
without or with the indicated inhibitors for 30 min followed by treat-
ment with M. avium for 30 min. Cell lysates were used to measure
MSK1 activity as described above. Data have been represented as
values relative to that obtained in cells treated with M. avium (100%).
Results in A and B are the means  S.D. of three independent experi-
ments. C, cells were transfected with wild type FLAG-MSK1 or domi-
nant-negative MSK1 (MSK1(dn)) followed by challenge with M. avium
for 30 min. Lysates were prepared, separated on SDS-PAGE, and blot-
ted with anti-phospho-CREB antibody. The bottom panel is a blot using
anti-FLAG antibody to show equal loading. The blot shown is repre-
sentative of the results obtained in three independent experiments.
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the role of CREB inM. avium-induced COX-2 reporter activity.
Transfection of cells with dominant-negative CREB along
with the COX-2-luciferase construct led to an inhibition of
M. avium-driven COX-2 promoter activity (Fig. 5B).
CREB Is Phosphorylated in M. avium-stimulated Macro-
phages—CREB is a target of MSK1 (35). We examined whether
CREB phosphorylation is differentially regulated in untreated
and M. avium-challenged macrophages and whether MSK1
regulates this process. To test this, cells were transfected with
wild type or dominant-negative MSK1 and challenged with
M. avium. Lysates from M. avium-challenged and untreated
macrophages were probed with an antibody that specifically
recognizes CREB phosphorylated at Ser-133. Our results
showed that CREB phosphorylation was enhanced in
M. avium-challenged macrophages and that this was abrogated
in cells transfected with dominant-negative MSK1 (Fig. 6C).
We also examined whether the enhanced CREB phosphoryl-
ation correlated with differences in CREB-specific DNA bind-
ing. Nuclear extracts were prepared from untreated cells as
well as cells treated for 3.5 h withM. avium. Only extracts from
M. avium-treated cells showed binding to an oligonucleotide
sequence corresponding to the CREB-binding site of the COX-2
promoter (Fig. 4C). DNA binding was inhibited by excess un-
labeled oligonucleotide. No binding was observed when a mu-
tant CREB-binding oligonucleotide sequence was used (data
not shown). Anti-CREB antibody supershifted the band ob-
tained with the CREB-specific DNA probe suggesting that
CREB binds to the CRE element of the COX-2 promoter.
MSK1 Is Necessary For Regulating COX-2 Promoter-driven
Gene Expression in M. avium-challenged Macrophages—To as-
sess the effects of MSK1 on COX-2-promoter-driven luciferase
expression in M. avium-treated macrophages, cells pretreated
with H89 (Fig. 5A) or transfected with dominant-negative
MSK1 (Fig. 5B) were subsequently challenged with M. avium,
and luciferase gene expression was assayed. In each case, sup-
pression of MSK1 activity led to almost complete inhibition of
luciferase expression, suggesting that MSK1 plays an impor-
tant role in regulating activation of the COX-2 promoter fol-
lowing M. avium challenge. We further analyzed the role of
M. avium-mediated MSK1 activation on NF-B and CRE-
driven luciferase expression by transfecting cells with a lucif-
erase reporter gene fused downstream of either a 4 B ele-
ment or a 6 CRE element. M. avium could activate both
NF-B-driven (Fig. 5C) and CRE-driven (Fig. 5D) luciferase
expression in these cells. However, such activation was abro-
gated in cells in which MSK1 activity was inhibited by treat-
ment with H89. Transfection with dominant-negative MSK1
gave similar results (data not shown). These results defini-
tively demonstrated that MSK1 regulates both NF-B- and
CRE-driven gene expression triggered by M. avium. In this
regard, the effect ofM. avium was different from that observed
in the case of LPS. We observed that Escherichia coli LPS-
stimulated NF-B- and CRE-driven luciferase expression (Fig.
5, C and D). The latter effect could be inhibited in cells pre-
treated with H89 (Fig. 5D). However, NF-B- driven luciferase
expression could not be inhibited by pretreatment with U0126
or SB203580 or H89 (Fig. 5C).
DISCUSSION
High PGE2 concentrations during mycobacterial infection
cause down-regulation of cell-mediated immunity permitting
disease progression (36). The immunosuppressive effects of
prostaglandin E2 in relation to mycobacterial infection under-
score the need to understand the mechanisms regulating the
expression of the rate-limiting enzyme in prostaglandin syn-
thesis, COX-2. Animal models of tuberculosis have demon-
strated that blocking of COX-2 produced high inflammation
and expression of tumor necrosis factor- and interferon-.
Although previous reports have shown that virulent M. avium
stimulates the expression of COX-2, the signaling pathways
regulating COX-2 expression remain to be studied. The data
presented in this report focus on the role of signaling pathways
inM. avium-induced COX-2 gene transcription. Our data dem-
onstrate that M. avium-induced gene expression driven by the
COX-2 promoter depends on TLR2-dependent signaling con-
verging on the NF-B and CRE-elements present in the pro-
moter, but not on the C/EBP or the AP-1 elements. Mutation
at either the NF-B-binding site or at the CRE-binding site led
to a partial inhibition of M. avium-induced COX-2 promoter-
driven luciferase gene expression (Fig. 4A), whereas mutation
at both these sites completely inhibited luciferase expression.
At the same time, nuclear extracts from M. avium-challenged
macrophages effected electrophoretic mobility shifts of oligonu-
cleotides corresponding to the COX-2-gene specific NF-B and
CRE sites (Fig. 4, B and C). Transcription factor NF-B has
been shown to induce macrophage COX-2 in response to a
variety of stimuli (37). Rhee and Hwang (29) have demon-
strated that LPS triggers TLR4-mediated NF-B activation
leading to COX-2 gene expression. Our studies demonstrate
that TLR2 contributes toM. avium-induced COX-2 gene induc-
tion (Fig. 5). Suppressor IB- transfection led to inhibition of
COX-2 promoter activity as well as consensus NF-B-driven
promoter activity (Fig. 5, B and E). These results supported a
role of the canonical NF-B activation in M. avium-stimulated
COX-2 promoter activation. M. avium-induced canonical
NF-B activation was also observed by Giri et al. (38). In
addition to the classic pathway, TLRs are known to activate
downstream signaling cascades through small G proteins such
as Rac and Ras to mediate NF-B activation. We observed that
M. avium challenge led to association of Ras with TLR2 and a
FIG. 7.Model depicting theM. avium-
triggered signaling pathways regu-
lating COX-2 gene expression.
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rapid activation of Ras (Fig. 2). COX-2 promoter activation, as
well as activation of the consensus NF-B promoter relied on
TLR2/Ras-dependent ERK activation (Fig. 3A). In the classic
Toll signaling pathway, TLRs upon recognizing suitable li-
gands recruit MyD88/IRAK/TRAF6. This leads to the activa-
tion of MAPK kinase kinases such as TAK1. M. avium trig-
gered TLR2/TRAF6/TAK1-dependent p38 MAPK activation
(Fig. 3D). Both ERK and p38 MAPK were responsible for the
activation of the nuclear kinase MSK1. A combination of phar-
macological inhibitors of ERK and p38 completely inhibited
MSK1 activation (Fig. 6B). Inhibitors of either ERK or p38
(U0126 or SB203580, respectively) partially inhibited NF-B-
driven luciferase expression, whereas H89 could block lucifer-
ase expression completely (Fig. 5C). These results clearly dem-
onstrated that MSK1 plays an important role in M. avium-
triggered NF-B activation. This effect of M. avium on
RAW264.7 macrophages was different from that reported in
the case of LPS-driven COX-2 expression in RAW264.7, where
LPS-driven NF-B activation has been shown to occur inde-
pendent of ERK (39) or MSK1 (8) activation. Previous work by
Deak et al. (34) demonstrated that the transcription factors
CREB and ATF1 are physiological substrates of MSK1. In the
present study we also observed that M. avium induced phos-
phorylation of CREB in an MSK1-dependent manner (Fig. 6C).
In summary, M. avium triggers TLR2-dependent signaling
leading to the phosphorylation of ERK and p38 MAPKs, which
converge to activate MSK 1 (Fig. 7). MSK1 regulates both the
NF-B- and the CRE-driven gene transcription. Both phospho-
rylated CREB and NF-B are known to recruit histone acety-
lases such as CBP/p300, which in turn contribute to making the
promoter more accessible to transcription factors and help in
bridging the transcription factor-CBP complexes to compo-
nents of the basal transcription machinery (40). MSK1 phos-
phorylates histone H3 (41) and has also been identified as a
nuclear kinase for p65, phosphorylating p65 at serine 276 (42).
Our results point to the fact that MSK1-dependent changes,
likely at the level of the nucleosome, are prerequisite for
M. avium-driven COX-2 gene expression. The nature of nucleo-
some remodeling following M. avium infection is presently
under investigation.
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